SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-22-006882
Filing Date
2022-05-02
Accepted
2022-05-02 16:31:36
Documents
5
Period of Report
2022-06-14

Document Format Files

Seq Description Document Type Size
1 DEF 14A ntla_def_14a_2022.htm DEF 14A 1815578
2 GRAPHIC img88921341_0.jpg GRAPHIC 5398
3 GRAPHIC img88921341_1.jpg GRAPHIC 5398
4 GRAPHIC img88921341_2.jpg GRAPHIC 83495
5 GRAPHIC img88921341_3.jpg GRAPHIC 69670
  Complete submission text file 0000950170-22-006882.txt   2042966
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37766 | Film No.: 22882468
SIC: 2835 In Vitro & In Vivo Diagnostic Substances